CVRx, Inc.
CVRX- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001235912
No open-market purchases or sales by CVRx, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $78.7M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:43 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $53.3M (94.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $56.7M | $51.3M | $39.3M | $22.5M | $13.0M |
| Cost of revenue | $8.31M | $8.33M | $6.26M | $5.00M | $3.64M |
| Gross profit | $48.3M | $43.0M | $33.0M | $17.5M | $9.40M |
| Operating expenses | $99.6M | $102.4M | $76.1M | $60.0M | $35.4M |
| Research and development | $11.1M | $11.1M | $11.6M | $9.95M | $7.50M |
| Selling, general and administrative | $88.5M | $91.3M | $64.5M | $50.0M | $27.9M |
| Operating income | -$51.3M | -$59.5M | -$43.1M | -$42.5M | -$26.0M |
| Interest expense | – | – | $1.80M | $165.0K | $2.22M |
| Income tax | -$18.0K | $55.0K | $147.0K | $109.0K | $91.0K |
| Net income | -$53.3M | -$60.0M | -$41.2M | -$41.4M | -$43.1M |
| EPS, basic | $-2.04 | $-2.65 | $-1.99 | $-2.02 | – |
| EPS, diluted | $-2.04 | $-2.65 | $-1.99 | $-2.02 | – |
| Weighted shares, basic | 26.1M | 22.6M | 20.8M | 20.5M | – |
| Weighted shares, diluted | 26.1M | 22.6M | 20.8M | 20.5M | – |
| Margins and growth | |||||
| Gross margin | 85.3% | 83.8% | 84.1% | 77.8% | 72.1% |
| Operating margin | -90.5% | -116.0% | -109.7% | -189.3% | -199.2% |
| Net margin | -94.1% | -116.9% | -104.8% | -184.4% | -330.5% |
| Revenue growth, year over year | +10.4% | +30.5% | +74.9% | +72.4% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $75.7M | $105.9M | $90.6M | $106.2M | $142.1M |
| Accounts receivable | $10.7M | $9.27M | $7.55M | $5.50M | $2.56M |
| Inventory | $12.2M | $12.1M | $11.0M | $6.96M | $3.88M |
| Total current assets | $101.6M | $129.8M | $112.1M | $122.9M | $151.1M |
| Property, plant and equipment | $2.24M | $2.50M | $1.76M | $1.70M | $1.43M |
| Total assets | $104.8M | $133.4M | $115.2M | $124.9M | $152.5M |
| Accounts payable | $3.83M | $2.58M | $1.88M | $1.72M | $510.0K |
| Total current liabilities | $13.3M | $10.8M | $7.86M | $8.09M | $5.91M |
| Long-term debt | $49.5M | $49.3M | $29.2M | $6.75M | $0 |
| Total liabilities | $65.5M | $62.4M | $39.3M | $15.8M | $6.59M |
| Shareholders' equity | $39.3M | $71.1M | $75.9M | $109.2M | $146.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | -$40.2M | -$39.1M | -$39.0M | -$42.7M | -$27.7M |
| Capital expenditures | $580.0K | $1.36M | $591.0K | $685.0K | $1.18M |
| Free cash flow | -$40.8M | -$40.5M | -$39.6M | -$43.4M | -$28.9M |
| Stock-based compensation | $11.1M | $19.1M | $6.30M | $3.89M | $1.91M |
| Investing cash flow | -$580.0K | -$1.36M | -$591.0K | -$685.0K | -$1.18M |
| Financing cash flow | $10.5M | $55.9M | $24.0M | $7.49M | $111.9M |
| Net change in cash | -$30.2M | $15.4M | -$15.6M | -$35.9M | $83.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 19.5% | 37.1% | 16.0% | 17.3% | 14.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.